Hutchmed/As­traZeneca lung can­cer drug gets OK in Chi­na; Enan­ta re­ports PhIb da­ta for their oral he­pati­tis B pro­gram

A col­lab­o­ra­tion to treat non-small cell lung can­cer be­tween As­traZeneca and Hutchmed has been grant­ed ap­proval by Chi­nese reg­u­la­tors, the com­pa­ny an­nounced Tues­day.

The ap­proval for savoli­tinib is the first for the oral ty­ro­sine ki­nase in­hibitor. It was based on the pos­i­tive re­sults from Phase II tri­al in Chi­na with the MET ex­on 14 mu­ta­tion, which ac­counts for rough­ly 2-3% of pa­tients. The treat­ment is for pa­tients with NSCLC who are un­able to re­ceive chemother­a­py. Savoli­tinib demon­strat­ed an­ti-tu­mor ac­tiv­i­ty based on the ob­jec­tive re­sponse rate and dis­ease con­trol rate, though the com­pa­ny didn’t dis­close that da­ta.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER